{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:03:13Z","timestamp":1780459393220,"version":"3.54.1"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Pediatric patients have a better survival rate for lymphoid malignancies than adolescents and young adult patients (AYA) and current evidence suggests that asparaginase plays a role in improved response to treatment. This study aimed to evaluate if increasing age as a continuous variable demonstrated increasing toxicities to PEG\u2010asparaginase (PEG\u2010ASP) for those patients treated at a tertiary care pediatric hospital.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective chart review from 2007 to 2017 was conducted in the pediatric population at the Children's Hospital of Eastern Ontario (CHEO). Patients having received PEG\u2010ASP were included. Event incidence and risk related to age at diagnosis were assessed through parameter estimates and Wald chi\u2010square analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 75 adverse events were observed: 34\/186 (18.3%) experienced allergic reactions, 8\/186 (4.3%) pancreatitis, 31\/186 (16.7%) thrombosis, and 2\/186 (1.1%) hemorrhage. One hundred and eighty two patients had complete information for inclusion in our model. A correlation between age at diagnosis and higher risk of allergic reaction (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001) and pancreatitis (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.035) was observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Allergic reaction and pancreatitis following administration of PEG\u2010ASP have a higher risk of occurrence as age of diagnosis increases up to 18\u2009years of age. This includes the lower limit of traditionally defined AYA population of 15\u201339 and warrants precaution as PEG\u2010ASP is included in older populations treatment regimens at pediatric centers.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13867","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T04:19:26Z","timestamp":1663993166000},"page":"32-39","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The association of age and adverse events of <scp>PEG<\/scp>\u2010asparaginase in a pediatric tertiary care hospital; a retrospective review"],"prefix":"10.1111","volume":"110","author":[{"given":"Lesleigh","family":"Abbott","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology Children's Hospital of Eastern Ontario  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maia","family":"Claveau","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Children's Hospital of Eastern Ontario  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Tang","sequence":"additional","affiliation":[{"name":"Research Institute Children's Hospital of Eastern Ontario  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jameason","family":"Cameron","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Children's Hospital of Eastern Ontario  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Goulet","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Children's Hospital of Eastern Ontario  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1089\/jayao.2015.0014"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2009.03.003"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000343"},{"key":"e_1_2_10_5_1","unstructured":"Canadian Partnership Against Cancer.Adolescents & Young Adults with Cancer: A System Performance Report. Toronto (ON): Canadian Partnership Against Cancer.2017April. p. 15. Accessed June 17 2021.https:\/\/www.virtualhospice.ca\/Assets\/Report%20\u2010%20Adolescents%20and%20Young%20Adults%20with%20Cancer%20\u2010%20EN_20170425132935.pdf"},{"key":"e_1_2_10_6_1","unstructured":"Canadian Cancer Statistics Advisory Committee.Canadian Cancer Statistics 2019. Toronto ON: Canadian Cancer Society. Updated September 2019. Accessed June 17 2021. cancer.ca\/Canadian\u2010Cancer\u2010Statistics\u20102019\u2010EN."},{"key":"e_1_2_10_7_1","unstructured":"Childhood Leukemia \u2010 Cancer Stat Facts. SEER. Accessed June 14 2021.https:\/\/seer.cancer.gov\/statfacts\/html\/childleuk.html"},{"key":"e_1_2_10_8_1","unstructured":"Leukemia \u2010 Cancer Stat Facts. SEER. Accessed June 14 2021.https:\/\/seer.cancer.gov\/statfacts\/html\/leuks.html"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S106810"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010019\u201001120\u20101"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.596963"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102008\u201001\u2010130237"},{"key":"e_1_2_10_13_1","unstructured":"Pegaspargase Monograph for Professionals. Drugs.com. Accessed June 25 2021.https:\/\/www.drugs.com\/monograph\/pegaspargase.html"},{"key":"e_1_2_10_14_1","unstructured":"Pegaspargase \u2010 National Cancer Institute. Published May 10 2006. Accessed June 25 2021.https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/pegaspargase"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26200"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28930"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1211"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.073510"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.2708"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201010\u2010881961"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.137380"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22076"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02208"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.251686"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102141.2010.08524.x"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.4137\/CMO.S18991"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049\u20103848(20)30392\u20103"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13867","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13867","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T18:35:56Z","timestamp":1692470156000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1111\/ejh.13867"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13867","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,17]]},"assertion":[{"value":"2022-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}